mPhase/AlwaysReady, Inc., a micro and nanotechnology development company focused on advanced power and sensing solutions, today announced the completion of its 2008 strategic planning process, resulting in several new corporate developments that will accelerate the commercialization path of its revolutionary nanotechnology-based battery.
The money spent on printed and potentially printed electronics doubled in 2007, as did the number of organisations participating. There are now about 1500 organisations doing significant work, most of them being academic. In 2008, there will be much more emphasis on commercialisation and many more countries will join the fray.
Moscow State University and IBM announced details of an agreement to install a Blue Gene/P supercomputer at the Department of Computational Mathematics and Cybernetics. The new supercomputer, the first installation of the world famous Blue Gene computer in Russia, will be used for fundamental research in nanotechnology, new materials and life sciences.
pSivida Limited, a global drug delivery company, and Intrinsiq Materials Cayman Limited today announced that the assets of pSiNutria Limited, a wholly owned subsidiary of pSivida, has been sold to Intrinsiq Materials, a UK based venture capital backed company.
Written by the inventor of the Gas Dynamic Spray (GDS) technique, this first monograph on the topic brings the understanding of the GDS coating formation process to a new qualitative nanostructural level, while introducing it to industrial and technological experts so that they can develop a new generation of coatings materials.
Industrial Nanotech, Inc. announced that the Company's patented Nansulate energy saving protective coatings are now sold in 33 countries and applicants for Exclusive Distributor status are currently under review for the countries of Russia, India, Sweden, Brunei, Bulgaria, Romania, and Korea. Negotiations for placement of the Company's products in retail stores are underway in the US, New Zealand, Canada, and Europe.
Nanometrics Incorporated, a leading supplier of advanced metrology equipment to the semiconductor industry, will release its fourth quarter and fiscal year 2007 financial results after market close on February 20, 2008. A conference call to discuss the results will be held at 5 PM ET.
Yesterday, Onexim Group revealed its first project in the area of nanotechnology. It proposes to build a research and technology center in Moscow, which may cost more than USD 100 million to implement considering the required equipment, RBC Daily wrote today.
Zecotek Photonics Inc. officially announced the launch of its new computerized, high-power, high-resolution laser spectrometer. The device was specifically developed to meet a rapidly growing demand for higher precision spectrometry in nano- and bio-technological applications. Zecotek's latest offering pushes the limits of the precise spectral measurements and technological procedures required in these fields.
Abraxis BioScience, Inc., an integrated biotechnology company, today announced that the European Commission has granted marketing approval for ABRAXANE powder for suspension for infusion (an albumin-bound nanoparticle formulation of paclitaxel) for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
Applied DNA Sciences, Inc. announced that it has filed multiple patent applications to cover its latest developments in optical reporter markers. These reporters 'announce' the presence of the DNA markers to which they are attached.
Nanostellar CEO Pankaj Dhingra will join a list of distinguished panelists at the World Economic Form in Davos, Switzerland, to address the entrepreneurial opportunities created by global warming. The panel, which takes place January 24, 2008, will turn its attention to the opportunities that the development and growth of 'green' initiatives can play in job creation and economic stimulation.
Molecular Profiles, a global leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors, announces the latest addition to its comprehensive nanoscale analytical services offering, nanoPASSTM (nanoscale Predictive Analytical Screening Solution).
NanoViricides, Inc. reported today that they are on course with the development of nanoviricides drug candidates against highly pathogenic avian influenzas (HPAI) including H5N1 bird flu, and common influenza.